BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsConference / presentation

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in

Open original release

Related news

BCRXBioCryst Pharmaceuticals2026-04-28 11:00 EST

BioCryst to Present at Upcoming Investor Conferences

BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

KRYSKrystal Biotech2026-05-07 12:00 EST

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

ARWRArrowhead Pharmaceuticals2026-05-04 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

View all latest news

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a rare-disease company focused on hereditary angioedema and other complement-related conditions. The business is built around commercial execution in specialized, high-value indications.

Recent company news

BCRXBioCryst Pharmaceuticals2026-07-22 11:00 EST

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BCRXBioCryst Pharmaceuticals2026-07-15 11:00 EST

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

Stock data

Close
9.58 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States